Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma
Cancers · 06.05.2023 · 15 (9) · 2634
DOI: 10.3390/cancers15092634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 06.05.2023. Verfasst von Woo Sun Rou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although the roles of erythroblastic leukemia viral oncogene homolog 2 (ERBB2), neuregulin 4 (NRG4), and mitogen-inducible gene 6 (MIG6) in epidermal growth factor receptor signaling in hepatocellular carcinoma (HCC) and other malignancies have been previously investigated, the prognostic value of their serum levels in HCC remains undetermined. In the present study, correlations between serum levels and tumor characteristics, overall survival, and tumor recurrence were analyzed. Furthermore, the prognostic potential of the serum levels of these biomarkers was evaluated relative to that of alpha-fetoprotein. Both ERBB2 and NRG4 correlated with the Barcelona Clinic Liver Cancer stage, ERBB2 correlated with the tumor-maximal diameter, and NRG4 correlated with a tumor number. Cox proportional hazards regression analysis revealed that ERBB2 (hazard ratio [HR], 2.719; p = 0.007) was an independent prognostic factor for overall survival. Furthermore, ERBB2 (HR, 2.338; p = 0.002) and NRG4 (HR, 431.763; p = 0.001) were independent prognostic factors for tumor recurrence. The products of ERBB2 and NRG4 had a better area under the curve than alpha-fetoprotein for predicting 6-month, 1-year, 3-year, and 5-year mortality. Therefore, these factors could be used to evaluate prognosis and monitor treatment response in patients with HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chungnam National University Sejong Hospital, Sejong 30099, Republic of Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea.
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea.
- Clinical Trial Center, Statistics Office, Biomedical Research Institute, Chungnam National University Hospital, Daejeon 35015, Republic of Korea.
- Division of Endocrinology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea.
ORCID-Profile: Woo Sun Rou, Hyuk Soo Eun, Bon Jeong Ku
Zitieren
APA
Rou, W. S., Eun, H. S., Choung, S., Jeon, H. J., Joo, J. S., Kang, S. H., Lee, E. S., Kim, S. H., Kwon, I. S., Ku, B. J., & Lee, B. S. (2023). Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma. Cancers, 15(9), 2634. https://doi.org/10.3390/cancers15092634
Vancouver
Rou WS, Eun HS, Choung S, Jeon HJ, Joo JS, Kang SH, et al. Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma. Cancers. 2023;15(9):2634. doi:10.3390/cancers15092634
BibTeX
@article{Rou2023,
author = {Rou, Woo Sun and Eun, Hyuk Soo and Choung, Sorim and Jeon, Hong Jae and Joo, Jong Seok and Kang, Sun Hyung and Lee, Eaum Seok and Kim, Seok Hyun and Kwon, In Sun and Ku, Bon Jeong and Lee, Byung Seok},
title = {Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma},
journal = {Cancers},
year = {2023},
volume = {15},
number = {9},
pages = {2634},
doi = {10.3390/cancers15092634}
}
EUVIMED